2.43
2.97%
+0.07
Leap Therapeutics Inc stock is currently priced at $2.43, with a 24-hour trading volume of 153.94K.
It has seen a +2.97% increased in the last 24 hours and a -21.61% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.31 pivot point. If it approaches the $2.48 resistance level, significant changes may occur.
Previous Close:
$2.36
Open:
$2.34
24h Volume:
153.94K
Market Cap:
$92.98M
Revenue:
$1.50M
Net Income/Loss:
$-81.41M
P/E Ratio:
-0.3733
EPS:
-6.51
Net Cash Flow:
$-43.75M
1W Performance:
+2.10%
1M Performance:
-21.61%
6M Performance:
+8.00%
1Y Performance:
+173.03%
Leap Therapeutics Inc Stock (LPTX) Company Profile
Name
Leap Therapeutics Inc
Sector
Industry
Phone
617 714 0360
Address
47 Thorndike Street, Suite B1-1, Cambridge, MA
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-04-21 | Initiated | Mizuho | Buy |
Jun-04-21 | Resumed | Robert W. Baird | Outperform |
Jun-29-20 | Initiated | Piper Sandler | Overweight |
Feb-11-20 | Initiated | Robert W. Baird | Outperform |
Nov-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
Sep-13-19 | Resumed | Raymond James | Outperform |
Mar-07-17 | Initiated | Ladenburg Thalmann | Buy |
View All
Leap Therapeutics Inc Stock (LPTX) Latest News
Closing Strong: Leap Therapeutics Inc (LPTX) Ends at 2.16, Down -5.26 from Last Close – DWinneX - The Dwinnex
The Dwinnex
GSK to Boost Vaccine Portfolio With Affinivax Acquisition - Yahoo New Zealand News
Yahoo New Zealand News
There is no doubt that Leap Therapeutics Inc (LPTX) ticks all the boxes. – Sete News - SETE News
SETE News
GSK Gets FDA Nod for Measles, Mumps & Rubella Vaccine, Priorix - Yahoo Movies Canada
Yahoo Movies Canada
Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails - Yahoo Movies UK
Yahoo Movies UK
Analyst Estimates: Here's What Brokers Think Of Leap Therapeutics, Inc. (NASDAQ:LPTX) After Its First-Quarter Report - Yahoo New Zealand News
Yahoo New Zealand News
Leap Therapeutics Inc Stock (LPTX) Financials Data
Leap Therapeutics Inc (LPTX) Revenue 2024
LPTX reported a revenue (TTM) of $1.50 million for the quarter ending December 31, 2021.
Leap Therapeutics Inc (LPTX) Net Income 2024
LPTX net income (TTM) was -$81.41 million for the quarter ending December 31, 2023, a -49.12% decrease year-over-year.
Leap Therapeutics Inc (LPTX) Cash Flow 2024
LPTX recorded a free cash flow (TTM) of -$43.75 million for the quarter ending December 31, 2023, a +10.79% increase year-over-year.
Leap Therapeutics Inc (LPTX) Earnings per Share 2024
LPTX earnings per share (TTM) was -$4.82 for the quarter ending December 31, 2023, a +0.21% growth year-over-year.
About Leap Therapeutics Inc
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Cap:
|
Volume (24h):